Skip to content
10-K

Annual Report

Valion Bio, Inc. VBIO

0001437749-26-010343

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 17, 2026 2.88M sh
Capex FY 2025 · Dec 31, 2025 $38K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$7M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$5.73M
Cash And Equivalents FY 2025 · Dec 31, 2025 $12.65M
Cash And Equivalents FY 2025 · Dec 31, 2024 $2M
Stockholders Equity FY 2025 · Dec 31, 2025 $16.8M
Stockholders Equity FY 2025 · Sep 30, 2025 $3.41M
Stockholders Equity FY 2025 · Jun 30, 2025 $3.31M
Stockholders Equity FY 2025 · Dec 31, 2024 $2.54M
Stockholders Equity FY 2025 · Dec 31, 2023 $3.58M
Current Liabilities FY 2025 · Dec 31, 2025 $646K
Current Liabilities FY 2025 · Dec 31, 2024 $272K
Total Liabilities FY 2025 · Dec 31, 2025 $7.44M
Total Liabilities FY 2025 · Dec 31, 2024 $272K
Current Assets FY 2025 · Dec 31, 2025 $13.01M
Current Assets FY 2025 · Dec 31, 2024 $2.64M
Total Assets FY 2025 · Dec 31, 2025 $31.61M
Total Assets FY 2025 · Dec 31, 2024 $2.81M
Eps Basic FY 2025 · Dec 31, 2025 −$7.84
Eps Basic FY 2025 · Dec 31, 2024 −$19.68
Sga Expense FY 2025 · Dec 31, 2025 $4.77M
Sga Expense FY 2025 · Dec 31, 2024 $3.16M
Rd Expense FY 2025 · Dec 31, 2025 $3.13M
Rd Expense FY 2025 · Dec 31, 2024 $1.31M
Net Income FY 2025 · Dec 31, 2025 −$8.88M
Net Income FY 2025 · Dec 31, 2024 −$5.66M
Operating Income FY 2025 · Dec 31, 2025 −$7.9M
Operating Income restated FY 2025 · Dec 31, 2024 −$4.48M